2008 Scientific Sessions at PHA International PH Conference | Pulmonary Hypertension Association Online University

Scientific Sessions

2008 Scientific Sessions Introduction

Fagan, Karen.
Animal Models of Human Severe PAH

McMurty IF
Bosentan improves hemodynamics and delays time to clinical worsening in patients with mildly symptomatic pulmonary arterial hypertension: Results of the EARLY study

Galie N, Benza RL, Rubin LJ, et al.
Long-term Ambrisentan Therapy Provides Sustained Benefit in Patients with Pulmonary Arterial Hypertension

Oudiz RJ
Extramural Research Pulmonary Arterial Hypertension

Kiley JP
Pharmacogenomics

Weinshilboum R
Potential Role for the Bone Morphogenetic Antagonist Gremlin in Pulmonary Hypertension

Gaine S
Molecular and Hemodynamic Determinants of Right Ventricular Response to Pulmonary Hypertension

Champion HC
Mechanisms for Cardiac Dysfunction in the Metabolic Syndrome

Abel ED

Abstracts

Idiopathic Pulmonary Hypertension is Caused by a Fetal Phenotype of Arterial Diameter Network Organization Remodeling Under the Principle of Minimum Work

Allen RP, Milstein JM, Moon-Grady AJ, et al.
Functional Genetic Variations in BMPR2 and Other Signaling Pathways Modify Clinical Expression of Familial Pulmonary Arterial Hypertension

Austin ED, III PJA, Cogan JD, et al.
HHV-8 Infection of Pulmonary Microvascular Endothelial Cells – A Potential Mechanism for the Development of Pulmonary Arterial Hypertension

Bull TM, Meadows CA, Campbell TB, Geraci MA
Induced Metabolic Acidosis is Protective in a Rat Model of Hypoxic Pulmonary Hypertension: Direct Effect on Vascular Smooth Muscle Cell (VSMC) Proliferation and Migration

Christou H, Arons E, Mitsialis SA
Potential Role for the Bone Morphogenetic Antagonist Gremlin in Pulmonary Hypertension

Costello CM, Howell K, Cahill E, et al.
Protease Activated Receptor Ca2+-Linked Mitochondrial Reactive Oxygen Species are Essential for Endothelial/Leukocyte Adherence

Hawkins BJ, Solt LA, Chowdhury I, et al.
PY-STAT3: an Upstream Regulator in Pulmonary Artery Hypertension

Mathew R, Huang J, Olson S, Gewitz M
Progressive Dysfunction of Nitric Oxide Synthase in a Lamb Model of Chronically Increased Pulmonary Blood Flow: A role for oxidant stress

Oishi PE, Wiseman DA, Sharma S, Azakie A, Black SM, Fineman JR
Ixolaris, a Tissue Factor Inhibitor, Reduces Vascular Pruning and Delays Death in Rats with Established Pulmonary Arterial Hypertension

Swarthout RF, Meoli DF, Taubman MB, Francischetti I, Awad H, White RJ
Enhancement of TRPC6-mediated Ca2+ Entry in Pulmonary Artery Smooth Muscle Cells of Idiopathic Pulmonary Arterial Hypertension Patients

Yu Y, Safrina O, Rubin LJ, Cahalan MD, Yuan JXJ
Gene Variants in Caveolin-1 and Caveolin-2 in Patients with Idiopathic Pulmonary Arterial Hypertension

Zellner C, Liao W, Pullinger CR, et al.
Uric Acid Decreases NO Availability and Increases Arginase Activity in Cultured Pulmonary Artery Endothelial Cells

Zharikov S, Krotova K, H.Hu, et al.
Hemolysis-Induced Pulmonary Hypertension and Treatment with Infused or Inhaled Nitrite, or Inhaled NO in the Newborn Lamb

Blood AB, Schroeder H, Terry MH, Merrill-Henry J, Power GG
A Long-acting Prostacyclin Agonist with Thromboxane Inhibitory Activity for Pulmonary Hypertension

Kataoka M, Satoh T, Nagaya N, Ogawa S
Cell Therapy Confers Protection from Immunodeficiency-Associated Pulmonary Hypertension and Prevents Activation of Right Ventricular Fetal Gene Program

Nicolls MR, Long C, Amber K, Tamosiuniene R
Pharmacogenomics in PAH: Roles of Downstream Polymorphisms of the ET-1 Pathway

Olave NC, Benza RL, Wolkowicz PE, Grenett HE
Vascular Pharmacogenomics in a Surgical Shunt Model of Pulmonary Arterial Hypertension (PAH): Analysis by Endoarterial Biopsy

Rothman A, Mann D, Davidson S, et al.
Serotonin 2B Receptor Antagonist PRX-08066 Inhibits Monocrotaline-Induced Pulmonary Hypertension in Rats

Warburton RR, Gannon KS, Guevara O, et al.
High-Altitude Pulmonary Edema Susceptibility in Relation to Epigenetic Patterns of Pulmonary Distensibility and Arterial Fractal Network Design

Allen RP, Milstein JM, Moon-Grady AJ, et al.
Post-Splenectomy Pulmonary Hypertension: Characteristics of 49 Patients

Golbin JM, McGoon MD, Krowka MJ
Pulmonary Hypertension is Common in Patients with Valvular Heart Disease and Persists Following Valve Surgery

Hurewitz AN, Bartlett M, Schubach S
Effect of Hemodynamics and Functional Capacity on Survival in Patients with Sickle Cell Disease and Pulmonary Hypertension

Machado RF, Cuttica M, Hunter L, Coles W, Gladwin MT
Macrophage Migration Inhibitory Factor (Mif) as a Biomarker in the Assessment of Pulmonary Arterial Hypertension and Interstitial Lung Disease: a Preliminary Study

Omonuwa K, Talwar A, Hu M, et al.
Degree of Reduction in Functional Pulmonary Microvascular Surface Area in Pulmonary Arterial Hypertension Related to CTD is Proportional for Two Pulmonary Metabolic Activities

Orfanos SE, Langleben D, Dupuis J, et al.
Exercise Echocardiograms (EE) in Scleroderma Patients with Different Auto-antibodies
REVEAL Registry: Baseline Characteristics of the First 1226 Enrolled Patients

Badesch DB, Barst RJ, Benza RL, et al.
REVEAL Registry: Baseline Characteristics of Patients with Childhood-Onset PAH

Barst RJ, Ivy D, Badesch DB, et al.
TOPP: The First Multinational Registry in Pediatric Pulmonary Hypertension

Barst RJ, Beghetti M, Berger RMF, Humpl T, Raskob G, Schulze-Neick I
REVEAL: A Registry to Evaluate PAH Disease Management

McGoon MD, Badesch DB, Barst RJ, et al.
2007 Review of Utah Pulmonary Hypertension Genetics Project: Updated Revisions and Findings

Schmidt JW, Glissmeyer EW, Adams D, et al.
Survival of Patients with Pulmonary Arterial Hypertension (PAH) Associated with Anorexigens vs. Survival Predicted From NIH Registry on Primary

Schmidt JW, Glissmeyer EW, Wojciechowski BL, et al.
Thyroperoxidase Antibody is Not a Useful Screening Test for Thyroid Disease in Patients with Pulmonary Hypertension

Burger CD
Endothelin-1 and BNP Plasma Levels Predict Survival in Patients with Pulmonary Arterial Hypertension

Frantz RP, Robbins IM, Durst LA, Grill DE, McGoon MD, Burnett JC
Misclassification of Pulmonary Arterial Hypertension Due to Use of Pulmonary Capillary Wedge Pressure (PCWP) Rather Than Left-Ventricular End-Diastolic Pressure (LVEDP)

Halpern SD, Taichman DB
What Patients and their Relatives Think About Testing for BMPR2

Jones DL, Sandberg JC, Rosenthal MJ, Saunders RC, Hannig VL, Clayton EW
Intra- and Inter-grader Agreement for World Health Organization Functional Class Assignment Based on a Novel Questionnaire in Patients with Pulmonary Arterial Hypertension

Murugappan M, Taichman D, Williamson T, et al.
Role of BNP in Identifying Elevated Pulmonary Wedge Pressure in Patients with Pulmonary Hypertension

Navas V, Rahaghi N, Ramirez J, et al.
Elevated Indices of Collagen Synthesis in Pulmonary Arterial Hypertension

Zeenat S, Frost AE
In Patients with Pulmonary Hypertension, Right Heart Failure is Diagnosed by Precise Estimation of Right Atrial Pressure with Inspection of the Internal Jugular Vein and Additional Use of the Hepatojugular Reflux Technique

Satoh T, Niino K, Kawakami T, Karaoke M, Yoshikawa T, Ogawa S
Evaluating the Right Ventricle: Volume, Function, and Shape

Sheehan FH
External Doppler is an Accurate and Reproducible Method of Measuring Cardiac Output in Patients with Pulmonary Hypertension

Sundy R, Billadello J, Zhen J, Ahrens T, Chakinala M
Wide Variation in Clinicians’ Assessments of NYHA/WHO Functional Class

Taichman DB, McGoon MD, Harhay MO, Sager J, Gallop R, Palevsky HI
Baseline Hemodynamic Measurement as a Predictor for Heart-Lung Transplantation versus Lung Transplantation in Pulmonary Arterial Hypertension

Ishizawar D, Zhang J, Simon MA, McCurry KR, Mathier MA
Idiopathic Pulmonary Arterial Hypertension (IPAH) Recurring Within One Year After Bilateral Lung Transplantation (LT)

Snow JL, Palevsky HI, Archer-Chicko C, Carney KC, Sager JS
Prognostic Factors Associated with Survival in 860 PAH Patients Treated With Subcutaneous Treprostinil Over a 3 Year Period

Arneson C
Methods of Increasing Comprehensive and Efficient Patient Care: The Enhancement of a Pediatric Pulmonary Hypertension Program

Bagby M, Giver J, Hirsch R
Maintenance of Intravenous Prostacyclin Infusions during Magnetic Resonance Imaging Scan

Bair N, Banjac S, Minai O, Dweik R
TRIUMPH I: Efficacy and Safety of Inhaled Treprostinil Sodium in Patients with Pulmonary Arterial Hypertension (PAH)

Benza RL, Rubin L, McLaughlin V, et al.
Comparable Efficacy of Bosentan in Eisenmenger’s Syndrome Patients with Atrial Septal Defects and Ventricular Septal Defects

Berger RMF, Beghetti M, Galiè N, et al.
Comprehensive Pulmonary Rehabilitation Improves Exercise Capacity and Quality of Life in Patients with Pulmonary Hypertension

Connors GL, Hess S, Shumway J, Lamberti JP
Clinicopathologic Correlation of a Calcium Channel Responsive Patient with Idiopathic Pulmonary Arterial Hypertension (IPAH)

Cooke RK, Duarte AG, Eltorky MA, Boroumand N, Cowan DF
Multi-center Experience with the Transition to Treprostinil from Inhaled Iloprost in Pulmonary Arterial Hypertension

Frantz RP, McGoon M, Waxman A, et al.
Bosentan Improves Hemodynamics and Delays Time to Clinical Worsening in Patients with Mildly Symptomatic Pulmonary Arterial Hypertension: Results of the EARLY Study

Galie N, Rubin LJ, Hoeper MM, Jansa P, Kusic-Pajic A, Simonneau G
Inhaled Nitric Oxide in the Assessment of Pulmonary Hypertension

Hunt JM, Barker SA, Messenger JC, et al.
Prevention of Catheter Related Bloodstream Infections with a Closed Hub System and Connection Protection in Patients Receiving Prostanoid Therapy for Pulmonary Arterial Hypertension

Ivy D, Doran A, Calderbank M, Dolan S, Nyquist A
Bosentan for Inoperable Chronic Thromboembolic Pulmonary Hypertension: A Randomized, Placebo-Controlled Trial (BENEFiT)

Jaïs X, Ghofrani A, Hoeper MM, et al.
Clinical and Hemodynamic Factors Associated with Prognosis in Pulmonary Arterial Hypertension (PAH)

Kane GC, Slusser JP, Scott CG, Maradit-Kremers H, McGoon MD
Treatment Patterns and Predictors of Drug Therapy in Pulmonary Arterial Hypertension (PAH) Between 1995 and 2005

Maradit-Kremers H, Golbin JM, Slusser JP, Scott CG, Kane GC, McGoon MD
Long-term Ambrisentan Therapy Provides Sustained Benefit in Patients with Pulmonary Arterial Hypertension

Oudiz RJ, on behalf of the ARIES Study Group
Goal-Directed Combination Therapy in Pulmonary Arterial Hypertension (PAH): Study Design of COMPASS-3

Park M, Torres F, Gupta H, et al.
Change in Diastolic Pulmonary Arterial Pressure (dPAP) Predicts Changes in Cardiac Index (CI) in Pulmonary Arterial Hypertension (PAH): Hemodynamic Data Analysis of the Initial Randomized Placebo-Controlled Bosentan Study

Soto FJ, Girotra S
A 36-Month Survival Analysis of Patients Beginning Oral PAH Monotherapy: An Indication for Escalation of Therapy?

Tankersley MA, D’Albini LD, Ozanich AN, Whitman AJ
Management of Pulmonary Arterial Hypertension During Pregnancy

Thomas S, Duarte AG, Chin K, Torres F, Wen T, Vadhera RB
Oral Treprostinil Diethanolamine Provides Sustained Therapeutic Plasma Concentrations Over a Wide Range of Doses in Patients with Pulmonary Arterial Hypertension

White RJ, Allen R, Yehle D, et al.
What is the Most Effective Way to Market a New Pulmonary Hypertension Center?

Zeiger TK, Safford RE, Burger CD